Diabetes and cardiometabolic companies need senior growth leadership with an existing understanding of payer channels, clinical credibility, and patient acquisition. We embed a fractional CXO with category experience – at a fraction of the risk and cost of a full-time executive.
The Challenge
At your stage, a full-time growth executive is a big, slow bet
A senior CMO or CGO who understands health commands a high salary and equity, takes months to recruit, and is a hard bet to reverse if the fit is wrong. For a growth-stage cardiometabolic company, that is a lot of cost and time before you know it works. A fractional model gives you the senior judgment without committing to that bet before you need it fully.
Generalist growth leaders lack an understanding of payers and compliance
A growth leader from consumer or standard SaaS often does not grasp payer channels, eligibility-gated funnels, or claim rules, and learns them expensively on your time. The category punishes that learning curve with wasted spend and compliance mistakes. You need leadership that already knows how growth works when a payer is the buyer and a regulator is watching.
Founders end up leading growth without the time to do it
In the absence of a growth leader, the founder or CEO carries marketing, acquisition, and commercial strategy on top of everything else, and it gets fragmented attention. Decisions get delayed, channels go unmanaged, and growth stalls not from lack of opportunity but lack of ownership. Someone senior has to own growth, and it should not be the already-stretched founder.
Agencies handle execution but do not own accountability or strategy
Hiring agencies for execution without a leader to set strategy and hold the plan accountable produces disconnected activity and no one answerable for the number. Vendors optimize their slice, not your growth. What is missing is senior ownership that directs the agencies and owns the outcome, which is exactly what a fractional CXO provides.
How We Help
We embed a senior growth leader with real operating experience in health – someone who knows payer channels, eligibility-gated acquisition, and claim rules from practice, not theory – and put them in charge of your growth strategy. This is the [growth strategy](/services/strategy/) function run by someone who does not have to learn the category at your expense.
The fractional CXO begins with a candid assessment: what is truly constraining growth, which channels and buyers matter, and what is operating on autopilot or being handled by an overextended founder. That assessment converts a general feeling that growth has stalled into a focused, prioritized plan.
They own the strategy and guide execution instead of trying to do everything personally. They establish the plan, then coordinate the internal team and any agencies through our [marketing](/services/marketing/) practice, aligning execution around one strategy and making someone accountable for results. This turns fragmented vendor activity into directed effort.
They provide the category judgment a generalist does not have – how to acquire patients within platform restrictions, develop payer and provider channels, and remain compelling without crossing claim lines – so choices are driven by genuine pattern recognition rather than costly trial and error.
They implement measurement through our [measurement](/services/measurement/) practice so growth operates on real signals – qualified enrollment, retention, pipeline – while giving the founder a clear view of what works. Leadership without measurement amounts to opinion, which is why the two are delivered together.
We do not deliver a strategy deck and disappear. We embed senior growth leadership that owns the strategy, guides execution, and answers for the number.
What we deliver
- A senior growth leader embedded and owning your growth strategy
- An honest assessment of where growth is actually constrained
- Category judgment on payers, compliance, and patient acquisition
- Direction and accountability across internal team and agencies
- A measurement system so growth runs on real signal
- A path to a full-time hire when the role justifies one
A diabetes or cardiometabolic company does not need a growth leader learning payers and compliance at your expense – it needs someone who brings that pattern recognition already, and the fractional model provides that senior judgment and ownership without the time, cost, and risk of betting on a full-time executive.
Our Methodology
Our 90-day sprint quickly embeds senior growth leadership and puts it into action. Days 1-30 center on assessment and ownership: the fractional CXO determines where growth is constrained, which channels and buyers matter, and what is unmanaged, then assumes ownership of the growth plan. This phase concludes with a prioritized strategy and a clear understanding of the true bottlenecks.
Days 31-60 center on guiding execution. The CXO unifies the internal team and agencies around one strategy, makes category-specific decisions about channels and compliance, and establishes measurement so choices are based on real signals instead of opinion. Growth activity shifts from disconnected to directed.
Days 61-90 center on validation and handoff planning. The CXO adjusts the plan based on results, documents the growth operating process, and determines whether and when a full-time hire makes sense. Since the value comes from embedded leadership rather than a document, engagements commonly continue for several months, with the fractional position scaling down as internal ownership expands.
How We Work
During the first 30 days, the fractional CXO partners directly with your founder and leadership team to identify growth constraints and assume ownership of the plan. Expect frank working sessions, not a passive audit.
Days 30-60 move toward guiding execution. The CXO brings the internal team and any agencies together around one strategy, makes the category decisions, and establishes measurement, ensuring growth is led by an accountable owner rather than divided among the founder and vendors.
Days 60-90 focus on outcomes and planning the handoff. The CXO refines the plan using real signals, documents the growth operating model, and advises whether a full-time hire is justified yet. Because the value lies in embedded leadership, most engagements last several months, generally one to three days per week, scaling back as internal capabilities expand.
A senior operator with health growth experience leads the engagement, backed by specialists in strategy, marketing, and measurement as needed by the plan, giving the CXO a bench instead of leaving them to work alone.
- Senior ownership of growth instead of a stretched founder
- Category judgment on payers, compliance, and acquisition
- Agencies and internal team aligned to one accountable plan
- Growth run on real signal, not opinion
- A clear path to a full-time hire when justified
If your diabetes & cardiometabolic health company needs fractional cxo leadership, we should talk.
Expand your marketing team output with our experts
Let us take a custom approach to your growth goals by assembling and leading the best-in-class marketing team to support your next stage.
Frequently asked questions
What does a fractional CXO cost for a diabetes or cardiometabolic company?
A fractional CXO engagement generally costs $15K-$35K/month based on the time commitment, typically one to three days per week, representing a fraction of the loaded cost of a full-time senior growth executive. You gain senior ownership and judgment without the salary, equity, or recruiting time required for a permanent hire. Since the role is tailored to what you need right now, the investment is evaluated against growth unlocked rather than a full-time compensation package.
What does a fractional CXO really do for a cardiometabolic company?
They take ownership of your growth strategy, make category-specific decisions about payer channels, patient acquisition, and compliance, and lead the internal team and agencies so one person answers for the number. They also establish measurement to ensure growth operates on real signals. Put simply, they deliver the senior growth leadership a growth-stage health company requires without the expense of hiring it full-time.
What makes a fractional CXO different from an agency?
An agency handles a specific slice and optimizes within its own scope, whereas a fractional CXO owns the broader strategy, manages the agencies, and answers for the growth result. Without that senior ownership, vendor efforts remain fragmented and nobody is accountable for the number. The fractional CXO supplies the leadership layer that turns execution into growth.
How soon does a fractional CXO produce results?
Since they understand the category from the start, the assessment and initial strategic actions occur within the first 30 days instead of following a lengthy ramp. Meaningful gains in how growth operates usually appear during the first quarter, followed by channel and pipeline results as execution progresses. Avoiding a learning curve is precisely what makes the fractional approach fast.
How does a fractional CXO work with our existing team?
They join your leadership as an embedded member, partnering directly with the founder and guiding the internal team and agencies instead of remaining outside the business as a consultant. Reporting and working cadence are structured to keep them visible and accountable, rather than merely advisory. As internal capabilities expand, the fractional role scales back, creating the intended path toward a full-time hire when justified.
When should a cardiometabolic company choose a fractional CXO over a full-time one?
A fractional CXO makes sense when you require senior growth leadership and category judgment, but a full-time position is not yet warranted or the risk of that bet is unaffordable. It is well suited to growth-stage companies where the founder still owns growth or agencies operate without management. If your diabetes or cardiometabolic company needs a growth leader but hiring full-time seems premature, we should talk.
